Summary
Elevance Health, Inc. filed an 8-K on June 12, 2024, primarily to reaffirm its financial guidance for the full year 2024. The company indicated that officers will be speaking with investors and intend to reaffirm the previously issued net income guidance. Specifically, Elevance expects full-year 2024 net income to be greater than $34.05 per diluted share. This includes an estimated $3.15 per diluted share attributed to net unfavorable items. Excluding these specific unfavorable items, Elevance Health continues to anticipate adjusted net income to be greater than $37.20 per diluted share. Investors should note that this guidance is based on information available as of the first quarter of 2024 earnings release and does not incorporate any further adjustments not previously disclosed. The filing also includes standard forward-looking statements and risk factors that investors should consider.
Key Highlights
- 1Elevance Health reaffirms its full-year 2024 net income guidance.
- 2The company expects full-year 2024 net income to be greater than $34.05 per diluted share.
- 3Net unfavorable items are estimated to impact EPS by approximately $3.15.
- 4Excluding these items, adjusted net income is projected to be greater than $37.20 per diluted share.
- 5The guidance is based on information from the Q1 2024 earnings release.
- 6No additional adjustment items beyond those reported in Q1 2024 are included in the reaffirmed guidance.
- 7The filing serves as a Regulation FD disclosure for upcoming investor communications.